science
Sun Pharma Agrees to Acquire Organon in $75 Billion Cash Deal
Sun Pharma has signed a definitive agreement to acquire Organon for $75 billion in cash. The deal sets the acquisition price at $00 per share and is expected to close in early 2027. It remains subject to regulatory and stockholder approvals.
FI
ai-cio.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
has agreed to acquire Organon in a cash transaction valued at $75 billion, according to a report from @FirstSquawk. The acquisition price is set at $00 per share in cash, the report stated.
The transaction is expected to close in early 2027, @FirstSquawk reported. It remains pending regulatory and stockholder approvals, according to the report.
The deal involves Sun Pharma, an India-based pharmaceutical company, acquiring Organon, a U.S.-based firm focused on women's health and biosimilars. This acquisition could combine resources in the pharmaceutical sector, though specific details on strategic benefits were not provided in the report.
Stakeholders affected include Organon stockholders, who would receive the cash payment upon approval. Next steps involve obtaining necessary approvals from regulators and stockholders before the expected closure date.
